The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Desquamative Interstitial Pneumonia (DIP)

A rare smoking-related interstitial lung disease characterized by diffuse intra-alveolar accumulation of pigmented macrophages and mild interstitial inflammation; a smoking-cessation–responsive disease in 60–80 percent of cases, with corticosteroids as second-line therapy.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Desquamative Interstitial Pneumonia (DIP)?

Desquamative interstitial pneumonia (DIP) is one of the major idiopathic interstitial pneumonias defined by the ATS/ERS classification, characterized histologically by uniform diffuse intra-alveolar accumulation of pigmented (smoker) macrophages with mild interstitial inflammation, mild fibrosis, and preserved alveolar architecture. The term 'desquamative' was a historical misnomer (originally thought to represent desquamated alveolar epithelial cells) — the cells are actually intra-alveolar macrophages with cytoplasmic smoker pigment.

Etiology and epidemiology: 90 percent of patients are current or former cigarette smokers (smoking-related ILD); rare non-smoking-related cases associated with environmental dust exposures (organic dusts, marijuana, hard metals, asbestos), connective tissue diseases (rheumatoid arthritis, systemic sclerosis), drugs (nitrofurantoin, sirolimus, tocainide), congenital surfactant protein C mutations (in children), and idiopathic. Mean age 30–50 years (younger than IPF), male predominance 2:1.

Diagnosis: HRCT shows bilateral ground-glass opacities with lower-lobe and peripheral predominance, often with centrilobular distribution and small cystic changes; reticular changes minimal (vs IPF); honeycombing rare. Surgical lung biopsy is gold standard for definitive diagnosis (transbronchial cryobiopsy increasingly used) showing uniform diffuse intra-alveolar pigmented macrophages, mild interstitial chronic inflammation and minimal fibrosis, no granulomas, no temporal heterogeneity. Differential: respiratory bronchiolitis-ILD (RB-ILD, similar but bronchiolocentric distribution and milder), nonspecific interstitial pneumonia (NSIP), hypersensitivity pneumonitis, alveolar proteinosis, alveolar hemorrhage.

Symptoms

Subacute progressive dyspnea on exertion (weeks to months)
Dry persistent cough
Inspiratory bibasilar fine crackles (Velcro crackles in some)
Digital clubbing (in 50 percent — more common than in RB-ILD)
Fatigue, weight loss
Mild hypoxemia at rest, worse with exertion
Long-term smoking history (current or former, mean > 30 pack-years)
Less commonly chest pain, hemoptysis, fever

Risk Factors

Current or former cigarette smoking (most important — 90 percent of cases)
Heavy occupational dust exposures (hard metals, organic dusts)
Marijuana smoking
Connective tissue disease (rheumatoid arthritis, systemic sclerosis)
Drug exposure (nitrofurantoin, sirolimus, tocainide, leflunomide)
Surfactant protein C gene mutations (rare, presents in childhood)
Family history of ILD (familial pulmonary fibrosis)
Male sex (2:1 male predominance)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Progressive shortness of breath in smoker over weeks to months
  • Persistent dry cough not responding to typical bronchodilators
  • New finger clubbing in adult smoker
  • Bibasilar crackles on examination
  • Diagnosis of interstitial lung disease — pulmonary referral
  • Hypoxemia (low oxygen saturation) on exertion
  • Worsening DIP despite smoking cessation — escalation needed
  • Connective tissue disease symptoms in patient with ILD

Treatment Methods

01
Diagnostic: detailed smoking and occupational/environmental exposure history, autoimmune panel (ANA, RF, anti-CCP, ANCA, myositis panel), HRCT chest (high-resolution computed tomography), pulmonary function tests (restrictive pattern, low DLCO), six-minute walk test with pulse oximetry, BAL (bronchoalveolar lavage — pigmented smoker macrophages, neutrophils, eosinophils variable)
02
Surgical lung biopsy or transbronchial cryobiopsy if diagnosis uncertain after non-invasive evaluation
03
Smoking cessation is the cornerstone — single most effective intervention; 60–80 percent of patients improve clinically and radiographically with cessation alone over months; multidisciplinary support (counseling, NRT, varenicline, bupropion)
04
Avoid inhaled environmental triggers (occupational dusts, marijuana, secondhand smoke)
05
Oral corticosteroids (prednisone 0.5–1 mg/kg/day, 4–8 weeks then taper over 6–12 months) for patients with significant symptoms, hypoxemia, or progression despite smoking cessation; expect clinical and radiologic improvement in 60–70 percent
06
Steroid-sparing agents for refractory cases or steroid intolerance: azathioprine, mycophenolate mofetil, cyclophosphamide (rarely used), rituximab (case reports)
07
Treat associated conditions: connective tissue disease management with rheumatology; remove offending drug; treat surfactant deficiency with appropriate therapy in pediatric cases
08
Supportive: pulmonary rehabilitation, supplemental oxygen if hypoxemic at rest or with exertion, vaccinations (influenza, pneumococcal, COVID-19), GERD treatment if present
09
Lung transplantation evaluation for end-stage progressive disease unresponsive to therapy
10
Long-term follow-up every 3–6 months: PFT, six-minute walk test, HRCT to assess response and detect progression to fibrotic ILD; prognosis generally favorable with smoking cessation (5-year survival 70–90 percent) but worse if continued smoking or progression to fibrosis

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.